HIGH-DOSE CISPLATIN AND BLEOMYCIN NEOADJUVANT CHEMOTHERAPY PLUS RADICAL SURGERY IN LOCALLY ADVANCED CERVICAL-CARCINOMA - A PRELIMINARY-REPORT

被引:57
作者
PANICI, PB [1 ]
GREGGI, S [1 ]
SCAMBIA, G [1 ]
RAGUSA, G [1 ]
BAIOCCHI, G [1 ]
BATTAGLIA, F [1 ]
CORONETTA, F [1 ]
MANCUSO, S [1 ]
机构
[1] UNIV CATTOLICA SACRO CUORE, DEPT GYNECOL & OBSTET, 8 LARGO AGOSTINO GEMELLI, I-00168 ROME, ITALY
关键词
D O I
10.1016/0090-8258(91)90310-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One course of chemotherapy containing cisplatin and bleomycin as a neoadjuvant treatment was given to 26 consecutive patients with previously untreated stage IB (bulky disease)-III cervical carcinoma and followed by radical surgery. After chemotherapy responses were detected in 23 patients (5 complete and 18 partial; overall, 88%) and permitted radical surgery in 21 cases (81%). Surgery consisted of type III-IV radical hysterectomy plus systematic para-aortic and pelvic lymphadenectomy. At histologic examination, complete responses were found in 5 (19%) and partial responses in 16 (62%) cases. The average number of lymph nodes removed was 61 (range, 38-118). A lower than expected incidence of lymph node metastases was detected ( 2 21, 9.5%). The chemotherapy-induced toxicity was mainly represented by nausea and vomiting. Chemotherapy did not seem to complicate surgery in these circumstances, even though moderate-degree postoperative complications occurred in 48% of cases. Eighteen months median follow-up time (range, 11-23) from hystological diagnosis has been reached in the operated patients, and no recurrences have been detected so far. © 1991.
引用
收藏
页码:212 / 216
页数:5
相关论文
共 38 条
[1]  
BAKER CH, 1981, BRIT J OBSTET GYNAEC, V88, P1192
[2]  
BEHRENS BC, 1985, P AM ASSOC CANC RES, V26, P262
[3]   HIGH-DOSE PLATINUM FOR THE TREATMENT OF REFRACTORY OVARIAN-CANCER [J].
BRUCKNER, HW ;
WALLACH, R ;
COHEN, CJ ;
DEPPE, G ;
KABAKOW, B ;
RATNER, L ;
HOLLAND, JF .
GYNECOLOGIC ONCOLOGY, 1981, 12 (01) :64-67
[4]   V-FACTOR (TUMOR VOLUME) AND T-FACTOR (FIGO CLASSIFICATION) IN THE ASSESSMENT OF CERVIX CANCER PROGNOSIS - THE RISK OF LYMPH-NODE SPREAD [J].
DARGENT, D ;
FROBERT, JL ;
BEAU, G .
GYNECOLOGIC ONCOLOGY, 1985, 22 (01) :15-22
[5]   EFFICACY AND SAFETY OF HIGH-DOSE CISPLATIN AND CYCLOPHOSPHAMIDE WITH GLUTATHIONE PROTECTION IN THE TREATMENT OF BULKY ADVANCED EPITHELIAL OVARIAN-CANCER [J].
DIRE, F ;
BOHM, S ;
ORIANA, S ;
SPATTI, GB ;
ZUNINO, F .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 25 (05) :355-360
[6]   PHASE-III STUDY ON THE TREATMENT OF WOMEN WITH CERVICAL-CANCER, STAGE-IIB, STAGE-IIIB, AND STAGE-IVA (CONFINED TO THE PELVIS AND/OR PERIAORTIC NODES), WITH RADIOTHERAPY ALONE VERSUS RADIOTHERAPY PLUS IMMUNOTHERAPY WITH INTRAVENOUS CORYNEBACTERIUM-PARVUM - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
DISAIA, PJ ;
BUNDY, BN ;
CURRY, SL ;
SCHLAERTH, J ;
THIGPEN, JT .
GYNECOLOGIC ONCOLOGY, 1987, 26 (03) :386-397
[7]   THE INTEGRATION OF CHEMOTHERAPY INTO THE MANAGEMENT OF LOCALLY ADVANCED CERVICAL-CANCER - A PILOT-STUDY [J].
FRIEDLANDER, ML ;
ATKINSON, K ;
COPPLESON, JVM ;
ELLIOT, P ;
GREEN, D ;
HOUGHTON, R ;
SOLOMON, HJ ;
RUSSELL, P ;
TATTERSALL, MHN .
GYNECOLOGIC ONCOLOGY, 1984, 19 (01) :1-7
[8]  
HRYNIUK WM, 1987, SEMIN ONCOL, V14, P3
[9]   2-YEAR SURVIVAL - PREOPERATIVE ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF CERVICAL-CANCER STAGE-IB AND STAGE-II WITH BULKY TUMOR [J].
KIM, DS ;
MOON, H ;
KIM, KT ;
HWANG, YY ;
CHO, SH ;
KIM, SR .
GYNECOLOGIC ONCOLOGY, 1989, 33 (02) :225-230
[10]   PRIMARY CHEMOTHERAPY AND POSTOPERATIVE ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF SQUAMOUS-CELL CARCINOMA OF THE UTERINE CERVIX [J].
KIM, DS ;
MOON, H ;
KANG, KJ .
GYNECOLOGIC ONCOLOGY, 1985, 22 (01) :59-64